Business Combination Registration · S-4
Adicet Bio, Inc.
ACETNASDAQEQUITYCurrent
Business Combination Registration
Company context
Adicet Bio, Inc. is a clinical-stage biotechnology company discovering and developing a broad pipeline of allogeneic gamma delta T cell therapies, engineered with chimeric antigen receptors (CARs), alongside differentiated in vivo CAR-T therapies with the potential to redefine treatment across autoimmune diseases, hematologic malignancies and solid tumors. For more information, please visit our website at https://www.adicetbio.com.
Current securities
Recent company filings
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsNov 13, 2026
- 10-Q filingNov 5, 2026
- Results of Operations and Financial ConditionNov 5, 2026
- SCHEDULE 13G/A - filed by FRANKLIN TEMPLETON INC regarding Adicet Bio, Inc.Oct 28, 2026
- Regulation FD Disclosure · Other EventsSep 28, 2026
As-filed source
As filedOpen full document ↗